Tris Pharma's allergy drug for children gets FDA OK

04/4/2013 | Drug Store News

The FDA approved Tris Pharma's Karbinal ER, or carbinoxamine maleate, for pediatric patients 2 years and older, to treat seasonal and perennial allergic rhinitis. The treatment is the first extended-release histamine receptor blocking agent for children's allergies, Tris said.

View Full Article in:

Drug Store News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Associate Manager, Regulatory Affairs
Stryker
Mahwah, NJ
Associate General Counsel
Patient-Centered Outcomes Research Institute
Washington, D.C , DC
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC